Kangpu Closes $13.8 Million B Round for Protein Ubiquitination Candidates
publication date: Sep 1, 2023
Shanghai Kangpu Biopharmaceuticals closed a $13.8 million B funding round to advance a portfolio of small molecule drugs based on targeted protein ubiquitination and degradation mechanisms. The company has developed a portfolio of six drugs that address needs in solid tumors, hematologic malignancies, autoimmune diseases, and inflammatory disorders. Two of these have started US clinical trials. In 2019, Kangpu completed a $14 million Pre-B financing. Investors in the latest B round included V-Capital, Northern Light Ventures, Yijing Capital, Realharmongy Capital and Xiaochi Capital. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.